CompletedPhase 2NCT00271635
Ascorbic Acid Treatment in CMT1A Trial (AATIC)
Studying Autosomal dominant Charcot-Marie-Tooth disease type 2
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Principal Investigator
- C. Verhamme, MDDepartment of Neurology, Academic Medical Center, University of Amsterdam
- Intervention
- Placebo(drug)
- Enrollment
- 13 enrolled
- Eligibility
- 12-25 years · All sexes
- Timeline
- 2006 – 2007
Study locations (1)
- Department of Neurology Academic Medical Center University of Amsterdam, Amsterdam, P.O.Box 22660, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00271635 on ClinicalTrials.govOther trials for Autosomal dominant Charcot-Marie-Tooth disease type 2
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT01193088Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2University of Iowa
- RECRUITINGNCT01193075Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and OthersMichael Shy
See all trials for Autosomal dominant Charcot-Marie-Tooth disease type 2 →